Vortioxetine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Vortioxetine |
| DrugBank ID | DB09068 |
| Brand Names (EU) | Brintellix |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.54% |
Approved Indication (EMA)
Treatment of major depressive episodes in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | endogenous depression | 99.54% | DL |
| 2 | anxiety disorder | 99.44% | DL |
| 3 | neurotic disorder | 99.24% | DL |
| 4 | major depressive disorder | 99.15% | DL |
| 5 | neurotic depression | 99.09% | DL |
| 6 | melancholia | 99.09% | DL |
| 7 | benign paroxysmal torticollis of infancy | 99.07% | DL |
| 8 | unipolar depression | 99.05% | DL |
| 9 | dysthymic disorder | 99.02% | DL |
| 10 | agoraphobia | 98.98% | DL |
| 11 | Ohdo syndrome and variants | 98.71% | DL |
| 12 | Keppen-Lubinsky syndrome | 98.53% | DL |
| 13 | blepharophimosis - intellectual disability syndrome, Ohdo type | 98.26% | DL |
| 14 | congenital isolated adrenocorticotropic hormone deficiency (disease) | 97.92% | DL |
| 15 | ligneous conjunctivitis | 97.85% | DL |
| 16 | autosomal dominant slowed nerve conduction velocity | 97.67% | DL |
| 17 | vitamin B12-responsive methylmalonic acidemia | 96.86% | DL |
| 18 | phobic disorder | 95.81% | DL |
| 19 | childhood apraxia of speech | 95.30% | DL |
| 20 | surfactant metabolism dysfunction, pulmonary | 94.50% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.